Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Divi's Laboratories Ltd.
NSE: DIVISLAB
|
BSE: 532488
|
ISIN: INE361B01024
|
Industry: Pharmaceuticals
Analyst Buy
|
Expensive Star
6642.5000
0.00
(
0.00
%)
NSE
Jan 07, 2026
15:31 PM
34.06% Gain from 52W Low
Volume:
423.9K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Divi's Laboratories Ltd.
07 Nov 2020, 12:00AM
Analyst Buy
Divi's Labs (ADD): Flawless execution drives Q2 beat upgrade to ADD
Accumulate:
Divi's Laboratories Ltd.
by
BOB Capital Markets Ltd.
Target: 3520
Recommendation
Target
BOB Capital Markets Ltd.
Divi's Labs (DIVI) retained its strong execution in Q2, reporting an 18% EBITDA beat.
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended
Don't be boring, unless you are an investor
The Baseline |
07 Jan 2026, 07:39PM
India’s electric cars see growth amid tough competition in 2025
The Baseline |
07 Jan 2026, 05:00PM
Custom synthesis business drives growth for Divi’s Laboratories
|
10 Mar 2022